Genelux (GNLX) Competitors $3.06 -0.02 (-0.65%) Closing price 04:00 PM EasternExtended Trading$3.06 0.00 (-0.16%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNLX vs. RAPP, RGNX, PRTC, MBX, TRML, RZLT, PRME, ERAS, TECX, and SLDBShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Rapport Therapeutics (RAPP), REGENXBIO (RGNX), PureTech Health (PRTC), MBX Biosciences (MBX), Tourmaline Bio (TRML), Rezolute (RZLT), Prime Medicine (PRME), Erasca (ERAS), Tectonic Therapeutic (TECX), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Its Competitors Rapport Therapeutics REGENXBIO PureTech Health MBX Biosciences Tourmaline Bio Rezolute Prime Medicine Erasca Tectonic Therapeutic Solid Biosciences Rapport Therapeutics (NASDAQ:RAPP) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk. Do analysts recommend RAPP or GNLX? Rapport Therapeutics presently has a consensus target price of $28.00, indicating a potential upside of 83.97%. Genelux has a consensus target price of $17.75, indicating a potential upside of 480.07%. Given Genelux's stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than Rapport Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has better valuation and earnings, RAPP or GNLX? Genelux has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapport TherapeuticsN/AN/A-$78.31M-$3.45-4.41Genelux$10K11,554.56-$29.87M-$0.88-3.48 Is RAPP or GNLX more profitable? Rapport Therapeutics' return on equity of -25.48% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets Rapport TherapeuticsN/A -25.48% -24.63% Genelux N/A -93.04%-74.17% Do institutionals and insiders believe in RAPP or GNLX? 37.3% of Genelux shares are held by institutional investors. 9.3% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to RAPP or GNLX? In the previous week, Rapport Therapeutics had 3 more articles in the media than Genelux. MarketBeat recorded 6 mentions for Rapport Therapeutics and 3 mentions for Genelux. Genelux's average media sentiment score of 0.63 beat Rapport Therapeutics' score of 0.62 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGenelux beats Rapport Therapeutics on 11 of the 14 factors compared between the two stocks. Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$116.30M$2.91B$5.52B$9.32BDividend YieldN/A2.46%4.25%4.05%P/E Ratio-3.4820.3628.1519.68Price / Sales11,554.56304.13438.33100.29Price / CashN/A42.3835.5357.53Price / Book4.037.768.235.67Net Income-$29.87M-$55.11M$3.23B$257.51M7 Day Performance-11.56%0.95%-0.01%0.52%1 Month Performance-5.26%8.44%5.61%8.84%1 Year Performance16.79%-2.38%26.52%14.18% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux1.2045 of 5 stars$3.06-0.6%$17.75+480.1%+17.6%$116.30M$10K-3.4810RAPPRapport Therapeutics1.4646 of 5 stars$12.04flat$28.00+132.6%-42.5%$439.43MN/A-3.49N/ANews CoverageInsider TradeRGNXREGENXBIO3.9991 of 5 stars$8.43-3.5%$31.63+275.1%-36.0%$438.40M$83.33M-2.71370PRTCPureTech Health2.4832 of 5 stars$18.01flat$45.00+149.9%-22.1%$432.58M$4.83M0.00100News CoverageGap UpMBXMBX Biosciences1.7058 of 5 stars$12.88+3.3%$37.50+191.1%N/A$430.50MN/A0.0036Analyst ForecastGap UpTRMLTourmaline Bio2.0381 of 5 stars$15.96-2.8%$49.33+209.1%+22.0%$421.75MN/A-4.9744News CoveragePositive NewsRZLTRezolute2.3899 of 5 stars$4.98+3.3%$11.83+137.6%+5.4%$412.20MN/A-4.3340High Trading VolumePRMEPrime Medicine3.8673 of 5 stars$3.80+22.2%$10.08+165.4%-25.8%$408.32M$3.85M-1.85234News CoverageHigh Trading VolumeERASErasca3.0897 of 5 stars$1.42-1.4%$4.57+221.9%-54.2%$407.93MN/A-2.29120TECXTectonic Therapeutic2.4884 of 5 stars$20.78-2.6%$83.60+302.3%+28.8%$398.47MN/A-2.84120Positive NewsSLDBSolid Biosciences3.242 of 5 stars$4.91-2.4%$15.10+207.5%-37.0%$389.90M$8.09M-1.64100News CoverageAnalyst Revision Related Companies and Tools Related Companies Rapport Therapeutics Alternatives REGENXBIO Alternatives PureTech Health Alternatives MBX Biosciences Alternatives Tourmaline Bio Alternatives Rezolute Alternatives Prime Medicine Alternatives Erasca Alternatives Tectonic Therapeutic Alternatives Solid Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNLX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredTrump has to finance $21 trillion. Here’s His Move…Trump needs $21 trillion to fund his agenda — and insiders believe he’s quietly preparing a major shift in the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNLX Stock Alerts